Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer: a retrospective analysis
1. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan 250117, China 2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan 250117, China
Bevacizumab, an anti-VEGF monoclonal antibody, has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC (ns-NSCLC). However, the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation. Thus, 59 patients were included in the present retrospective study, 22 patients in the bevacizumab plus pemetrexed and platinum (B+PP) group, and 37 patients in the pemetrexed and platinum (PP) group. For the entire cohort of patients, the median OS was 33.3 months, and the 1-year and 2-year overall survival rates were 88.5% and 67.8%, respectively. The median OS and 1-year and 2-year OS rates were 20.5 months, 70.3% and 0%, respectively, in the B+PP group and 33.4 months, 97.0% and 89.4%, respectively, in the PP group (P <0.001). The incidence of grade≥3 adverse events was higher in the B+PP group than in the PP group (27.3% vs. 10.8%, respectively; P=0.204). Univariate and multivariate analyses suggested that the receipt of≥5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS, whereas the addition of bevacizumab was an unfavorable prognostic factor. With increased toxicities, the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.
Number of first-line chemotherapy cycles (≥ 5 vs. < 5)
0.045
0.005–0.426
7.288
0.007
Maintenance (yes vs. no)
0.864
0.218–3.419
0.043
0.835
Thoracic radiation (yes vs. no)
0.176
0.015–2.117
1.875
0.171
Bevacizumab (yes vs. no)
13.733
1.855–101.675
6.579
0.010
Tab.4
1
F Bray, J Ferlay, I Soerjomataram, RL Siegel, LA Torre, A Jemal. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424 https://doi.org/10.3322/caac.21492
pmid: 30207593
2
RS Herbst, D Morgensztern, C Boshoff. The biology and management of non-small cell lung cancer. Nature 2018; 553(7689): 446–454 https://doi.org/10.1038/nature25183
pmid: 29364287
RK Jain. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7(9): 987–989 https://doi.org/10.1038/nm0901-987
pmid: 11533692
6
LM Ellis, DJ Hicklin. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008; 8(8): 579–591 https://doi.org/10.1038/nrc2403
pmid: 18596824
7
A Sandler, R Gray, MC Perry, J Brahmer, JH Schiller, A Dowlati, R Lilenbaum, DH Johnson. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542–2550 https://doi.org/10.1056/NEJMoa061884
pmid: 17167137
8
C Zhou, YL Wu, G Chen, X Liu, Y Zhu, S Lu, J Feng, J He, B Han, J Wang, G Jiang, C Hu, H Zhang, G Cheng, X Song, Y Lu, H Pan, W Zheng, AY Yin. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 2015; 33(19): 2197–2204 https://doi.org/10.1200/JCO.2014.59.4424
pmid: 26014294
9
M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, N Leighl, J Mezger, V Archer, N Moore, C Manegold. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): 1227–1234 https://doi.org/10.1200/JCO.2007.14.5466
pmid: 19188680
10
MH Cohen, J Gootenberg, P Keegan, R Pazdur. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007; 12(6): 713–718 https://doi.org/10.1634/theoncologist.12-6-713
pmid: 17602060
L Crinò, E Dansin, P Garrido, F Griesinger, J Laskin, N Pavlakis, D Stroiakovski, N Thatcher, CM Tsai, YL Wu, C Zhou. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11(8): 733–740 https://doi.org/10.1016/S1470-2045(10)70151-0
pmid: 20650686
13
SS Ramalingam, SE Dahlberg, CJ Langer, R Gray, CP Belani, JR Brahmer, AB Sandler, JH Schiller, DH; Eastern Cooperative Oncology Group Johnson. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008; 26(1): 60–65 https://doi.org/10.1200/JCO.2007.13.1144
pmid: 18165641
14
J Zhu, DB Sharma, SW Gray, AB Chen, JC Weeks, D Schrag. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012; 307(15): 1593–1601 https://doi.org/10.1001/jama.2012.454
pmid: 22511687
15
H Takeoka, K Yamada, Y Naito, N Matsuo, H Ishii, T Tokito, K Azuma, M Ichiki, T Hoshino. Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as a first-line treatment for advanced non-squamous non-small cell lung cancer in elderly patients. Anticancer Res 2018; 38(6): 3779–3784 https://doi.org/10.21873/anticanres.12661
pmid: 29848743
16
T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, YL Wu, I Bover, S Begbie, V Tzekova, B Cucevic, JR Pereira, SH Yang, J Madhavan, KP Sugarman, P Peterson, WJ John, K Krejcy, CP Belani. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374(9699): 1432–1440 https://doi.org/10.1016/S0140-6736(09)61497-5
pmid: 19767093
17
CP Belani, T Brodowicz, TE Ciuleanu, M Krzakowski, SH Yang, F Franke, B Cucevic, J Madhavan, A Santoro, R Ramlau, AM Liepa, C Visseren-Grul, P Peterson, WJ John, CC Zielinski. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012; 13(3): 292–299 https://doi.org/10.1016/S1470-2045(11)70339-4
pmid: 22336221
18
LG Paz-Ares, F de Marinis, M Dediu, M Thomas, JL Pujol, P Bidoli, O Molinier, TP Sahoo, E Laack, M Reck, J Corral, S Melemed, W John, N Chouaki, AH Zimmermann, C Visseren-Grul, C Gridelli. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31(23): 2895–2902 https://doi.org/10.1200/JCO.2012.47.1102
pmid: 23835707
19
A Lopez-Chavez, T Young, S Fages, L Leon, JH Schiller, A Dowlati, JR Brahmer, DH Johnson, A Sandler. Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol 2012; 7(11): 1707–1712 https://doi.org/10.1097/JTO.0b013e318265b500
pmid: 23059774
20
JD Patel, MA Socinski, EB Garon, CH Reynolds, DR Spigel, MR Olsen, RC Hermann, RM Jotte, T Beck, DA Richards, SC Guba, J Liu, B Frimodt-Moller, WJ John, CK Obasaju, EJ Pennella, P Bonomi, R Govindan. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 2013; 31(34): 4349–4357 https://doi.org/10.1200/JCO.2012.47.9626
pmid: 24145346
21
RA Soo, M Loh, TS Mok, SH Ou, BC Cho, WL Yeo, DG Tenen, R Soong. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol 2011; 6(6): 1030–1038 https://doi.org/10.1097/JTO.0b013e3182199c03
pmid: 21532500